No, that would need to be disclosed to the market. As OPT302 is their only drug candidate any contract regarding it would be material, thus disclosed. More likely, a few drug companies will make offers as soon as they see the results of the DME study.Yes, afaik, they are required under the listing rules to put out a 4C due to how small they are and that they lack any revenues.
Edit to add: I doubt the 4C will tell us anything at the moment that hasn't already been said by the company or to shareholders.
Heads up: OPT is about to skyrocket, page-39
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
56.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $695.5M | |||
| Open | High | Low | Value | Volume |
| 57.5¢ | 57.5¢ | 55.0¢ | $706.9K | 1.260M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 79437 | 55.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 57.0¢ | 174437 | 2 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| OPT (ASX) Chart |